Xigris Cmte. Invokes History Of Sepsis Failures; "Do It Right," Chair Says
Executive Summary
FDA and Lilly should not miss the opportunity to demonstrate unequivocally the efficacy of a sepsis product, FDA's Anti-Infective Drugs Advisory Committee Chair Barth Reller, MD, Duke University, said during the committee's review of Xigris Oct. 16.